Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of “Hold” from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.3750.

A number of brokerages have recently commented on MRVI. Wall Street Zen raised Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $2.95 on Monday. The company has a current ratio of 6.60, a quick ratio of 5.69 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $758.36 million, a P/E ratio of -3.28 and a beta of 0.43. The business has a fifty day simple moving average of $3.22 and a two-hundred day simple moving average of $3.33. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The firm had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. On average, equities analysts forecast that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently bought and sold shares of the business. Sprott Inc. bought a new position in Maravai LifeSciences during the 3rd quarter valued at about $29,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the third quarter valued at approximately $31,000. Abel Hall LLC purchased a new stake in Maravai LifeSciences in the third quarter worth approximately $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $33,000. Finally, Virtu Financial LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $34,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.